Medtronic is seeking regulatory clearance for an insulin pump that could expand its partnership with Abbott.
In its application to the Food and Drug Administration, Medtronic is seeking clearance for its MiniMed 780G pump as an alternate controller-enabled insulin pump.
If approved, the pump would be able to integrate with a continuous glucose monitoring sensor on Abbott's platform.
Related: FDA approves Medtronic’s adaptive technology for Parkinson’s
Medtronic also submitted an application seeking clearance for its SmartGuard algorithm as an interoperable automated glycemic controller. It would be used to automatically calculate medication doses based on factors like blood sugar levels and instruct the pump to deliver the appropriate dose.The MiniMed 780G pump is designed to be used with the SmartGuard algorithm, according to Medtronic.
In August, Medtronic announced a partnership with Abbott to work on an integrated continuous glucose monitor. As part of the agreement, Abbott would supply Medtronic with a continuous glucose monitor that works only with Medtronic’s smart dosing devices and software. The monitor would be sold by Medtronic.
